XML 34 R20.htm IDEA: XBRL DOCUMENT v3.25.3

Note 3 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2025

Notes Tables

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

		September 30,
		2025				2024
Common stock warrants			2,601,671				2,633,868
Stock options			995,374				533,159
			3,597,045				3,167,027

Schedule of Segment Reporting Information, by Segment [Table Text Block]

		Three Months Ended September 30,								Nine Months Ended September 30,
		2025				2024				2025				2024
Grant revenue		$	322,569			$	1,939,751			$	3,997,784			$	7,575,972
Research and development expenses:
Dementia with Lewy bodies			1,680,922				3,317,345				5,866,430				8,753,991
Frontotemporal dementia			313,438				2,581				846,664				2,581
Recovery after stroke			396,635				112,759				952,338				112,759
Other clinical* and preclinical			485,586				541,125				1,505,726				542,932
Personnel costs, excluding stock-based compensation			1,767,086				643,024				4,060,722				1,235,556
Stock-based compensation			133,169				42,224				378,029				146,358
Other research and development expenses, including CMC**			1,263,606				466,039				2,376,956				917,569
Total research and development expenses			6,040,442				5,125,097				15,986,865				11,711,746
General and administrative expenses:
Personnel costs, excluding stock-based compensation			1,087,467				1,168,151				3,797,765				2,968,276
Stock-based compensation			158,548				22,050				771,869				921,653
Professional fees			711,307				707,725				2,053,984				2,049,828
Insurance, taxes and similar fees			258,032				241,123				917,616				709,178
Other general and administrative expenses, including IT, facilities, supplies and similar costs***			110,972				71,878				433,043				201,601
Total general and administrative expenses			2,326,326				2,210,927				7,974,277				6,850,536
Other income			317,560				642,732				1,084,281				1,401,529
Net loss		$	(7,726,639	)		$	(4,753,541	)		$	(18,879,077	)		$	(9,584,781	)

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

+ Details

Name:	us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_TableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration